COMBIVENT Nebulizer Liquid 2.5ml (2.5ml)

About This Product

Qualitative and quantitative composition: Each 2.5 ml single dose unit contains 500 micrograms ipratropium bromide (as 520 micrograms ipratropium bromide monohydrate) and 3 mg salbutamol sulfate (corresponds to 2.5mg salbutamol base). Therapeutic indications: The management of bronchospasm in patients suffering from chronic obstructive pulmonary disease who require regular treatment with both ipratropium and salbutamol. COMBIVENT UDVs are intended for inhalation only and may be administered from a suitable nebuliser or an intermittent positive pressure ventilator. The single dose units must not be taken orally or administered parenterally. Treatment should be initiated and administered under medical supervision, e.g. in the hospital setting. Home based treatment can be recommended in exceptional cases (severe symptoms or experienced patients requiring higher doses) when a low dose rapid acting beta-agonist bronchodilator has been insufficient in providing relief after consultation with an experienced physician. The treatment with the nebuliser solution in UDVs should always be started with the lowest recommended dose (1 UDV). In very severe cases two unit dose vials may be required for symptom relief. Administration should be stopped when sufficient symptom relief is achieved.

Product Details